The benefits of frexalimab in people with relapsing MS have been sustained for up to three years in a clinical trial, data ...

India: A major advancement in cancer care has arrived in India with the launch of Tecentriq SC (atezolizumab) by Roche Pharma ...

An international research team has succeeded in elucidating key immunological and biochemical mechanisms underlying ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of ...

Jade Biosciences has dosed the first participant in its Phase II JUNIPER clinical trial, evaluating JADE101 for ...

Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma ...

Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (Nasdaq: JBIO), a cli ...

Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval ...

IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single ...

So AbCellera is a company based in Vancouver, Canada, also with offices in Montreal, Canada and in Sydney, Australia. Founded in 2012 out of our Founder and CEO, Carl Hansen's lab from the University ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...

DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European ...